EMA consults on proposed changes to guide on evaluating anticancer drugs
This article was originally published in SRA
Executive Summary
The European Medicines Agency is seeking feedback on proposed amendments to its guideline on evaluating human anticancer medicines, which deals with all stages of clinical drug development for the treatment of malignancies, including drug resistance modifiers or normal tissue protective compounds1,2.